HN2302

HN2302 is an experimental *in vivo* chimeric antigen receptor T-cell (CAR-T) therapy currently under investigation for the treatment of refractory generalized myasthenia gravis (MG). Developed by The Affiliated Hospital of Xuzhou Medical University, HN2302 represents a novel approach to CAR-T therapy where the genetic modification of T cells occurs directly within the patient's body following injection, rather than through the traditional, complex *ex vivo* manufacturing process. The therapy utilizes a viral vector to deliver a CAR transgene that programs endogenous T cells to identify and eliminate pathogenic B cells, specifically targeting the B-lymphocyte antigen CD19. By depleting these B cells, the therapy aims to reduce the production of autoantibodies that interfere with neuromuscular transmission. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and preliminary efficacy in adult patients with refractory generalized myasthenia gravis.